Head-to-head comparison
Invyncible vs Kin Meds
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Invyncible is a Florida telehealth platform pricing every GLP-1 dose program in the open, with all six of its compounding pharmacies named and patient-selectable.
From $149/mo (lowest dose rung) sema · From $180/mo (lowest dose rung) tirz · Verified August 2026
Marked down on: The entry price buys the smallest vial: the same plain semaglutide program runs $262.50 at 5 mg and $350 at 10 mg, which the FAQ confirms
Desk Score
Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s.
$149/mo (brand-name) sema · $149/mo (brand-name) tirz · Verified July 2026
Marked down on: Legal entity name and state of incorporation not publicly disclosed
FDAWarning letter issued to Kin Meds in February 2026. See the FDA warning-letter database.
Invyncible takes this head-to-head with the higher Desk Score, 73/100 (C) against 68/100 (C) for Kin Meds. Kin Meds still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Invyncible
73/100
C
Kin Meds
68/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Invyncible | Kin Meds |
|---|---|---|
| Semaglutide | From $149/molowest dose rung$149/mo (0.45 mg dose, compounded with glycine + B12) | $149/mobrand-name$149/mo (brand Wegovy) |
| Tirzepatide | From $180/molowest dose rung$180/mo (2.5 mg weekly, 4-week program, compounded) | $149/mobrand-name$149/mo (brand Zepbound) |
| Coverage | 46 states plus DC | Not listed on Kin Meds's site (checked July 2026) |
| Brand-name | Yes | Yes |
| Oral option | Yes | Yes |
| Best for | An open price list and a named, patient-selectable compounding pharmacy rather than an unnamed network. | Compounded and brand-name GLP-1 plus a longevity stack on one platform. |
| Desk Score | 73/100C | 68/100C |
The verdict
Desk pick — InvyncibleInvyncible takes this head-to-head with the higher Desk Score, 73/100 (C) against 68/100 (C) for Kin Meds. Kin Meds still holds its ground where its strengths line up with yours.
Choose Invyncible if…
An open price list and a named, patient-selectable compounding pharmacy rather than an unnamed network.
From $149/mo (lowest dose rung) sema · From $180/mo (lowest dose rung) tirz · 46 states plus DC
Choose Kin Meds if…
Compounded and brand-name GLP-1 plus a longevity stack on one platform.
$149/mo (brand-name) sema · $149/mo (brand-name) tirz
FDAWarning letter issued to Kin Meds in February 2026. See the FDA warning-letter database.
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Invyncible · Kin Meds.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs Invyncible
- CoreAge Rx vs Kin Meds
- Invyncible vs Ondra Health
- Kin Meds vs Vaylen
- Invyncible vs Vaylen
- Kin Meds vs PCOS Sisters
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.